ALG-1007 is a novel topical mitochondrial stabilizer in development for potential use in patients with dry eye disease. ALG-1007 demonstrated a strong signal in an ex-U.S. proof-of-concept clinical trial in which it showed a dose response curve and that it was generally well-tolerated. A second and larger ex-U.S. Phase 2 clinical trial was successfully completed.